Vidac Pharma

Vidac Pharma aims to cure cancer by targeting the tumor microenvironment and returning cancer cells to normal metabolism through a new paradigm in AI derived drug discovery – The Toposteric Effect.

The Tumor Microenvironment Challenge for Cancer Treatment Vidac Pharma TODAY in a Nutshell

<div style="margin-top: 0px;">Vidac Pharma aims to cure cancer by targeting the tumor microenvironment and returning cancer cells to normal metabolism through a new paradigm in AI derived drug discovery – The Toposteric Effect.</div><div style="margin-top: 10px;"><a href="index.php?option=com_content&view=article&id=95" class="g-owlcarousel-item-button button button-2">The Tumor Microenvironment Challenge</a></div><div style="margin-top: 10px;"><a href="index.php?option=com_content&view=article&id=96" class="g-owlcarousel-item-button button button-2">Vidac Pharma TODAY in a Nutshell</a></div>

Vidac Pharma aims to cure cancer by targeting the tumor microenvironment and returning cancer cells to normal metabolism through a new paradigm in AI derived drug discovery – The Toposteric Effect.

The Tumor Microenvironment Challenge

Vidac Pharma TODAY in a Nutshell

Skin Cancer

As the incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades, better treatment modalities are needed.

VDA-1102

VDA-1102 ointment is the FIRST in a new class of drugs that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.

Technology Spotlight

HK2 has a vital role in cancer metabolism. Vidac is creating innovative therapies for people suffering from a range of oncology and dermatology ailments.

Skin Cancer

As the incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades, better treatment modalities are needed.

VDA-1102

VDA-1102 ointment is the FIRST in a new class of drugs that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.

Technology Spotlight

HK2 has a vital role in cancer metabolism. Vidac is creating innovative therapies for people suffering from a range of oncology and dermatology ailments.

VDA-1102 VDAC/HK2 MOA

HKS N-terminal-helix flips out of place to allow VDAC's N-terminal-helix to replace it, thus binding the two proteins.

VDA-1102 Inhibits Cancer Proliferation

VDA-1102 demonstrated strong inhibition of cancer growth across multiple indications.

70% of a panel with 57 cancer models (2019-2021)

Threshold <2uM; Colony forming assay in 57 patient-derived tumors and cancer cell lines conducted at Oncotest GmbH, a division of Charles River Labs.

Pipeline

Vidac has built a portfolio of novel product candidates that target significant unmet medical needs in oncology and dermatology.

Vidac is creating innovative therapies for people suffering from a range of oncologic and dermatologic medical conditions.

Science: HK2 - A Major Driver of Cancer

VDA-1102 VDAC/HK2 MOA

VDA-1102 Inhibits Cancer Proliferation

Pipeline

Therapeutic Areas

News

VIDAC PHARMA LTD ANNOUNCES WIDER SPECTRUM AUTHORIZATION OF ITS CTCL PHASE 2 CLINICAL TRIAL.

Vidac Pharma Ltd.: New Chemical Entities Patent Granted

Vidac Pharma Secures EUR 20m Capital Commitment From GEM

VIDAC PHARMA ANNOUNCES INCLUSION OF THE FIRST PATIENT IN A PLACEBO CONTROLLED PHASE II STUDY